Marker Therapeutics
MRKR
28 hedge funds and large institutions have $5.67M invested in Marker Therapeutics in 2024 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 6 increasing their positions, 3 reducing their positions, and 4 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 3
0.02% more ownership
Funds ownership: 22.52% → 22.54% (+0.02%)
0% more funds holding
Funds holding: 28 → 28 (0)
0% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 4
48% less capital invested
Capital invested by funds: $10.9M → $5.67M (-$5.24M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
I
INVST
Indianapolis,
Indiana
|
+$79.1K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$75.6K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$51.5K |
| 4 |
BlackRock
New York
|
+$31.6K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$19K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WS
Wedbush Securities
Los Angeles,
California
|
-$377K |
| 2 |
IAIM
International Assets Investment Management
Orlando,
Florida
|
-$10.9K |
| 3 |
Northern Trust
Chicago,
Illinois
|
-$3.67K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$1.42K |
| 5 |
RAM
Riggs Asset Management
Dallas,
Pennsylvania
|
-$791 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
JP Morgan Chase
New York
| $107 | – | – | – |
|
|
VCM
27
Versant Capital Management
Phoenix,
Arizona
| $42 | – | – | – |
|
28
Fidelity Investments
Boston,
Massachusetts
| $34 | – | – | – |
|
|
WS
29
Wedbush Securities
Los Angeles,
California
| – | -$377K | -69,500 | Closed |
|
|
IAIM
30
International Assets Investment Management
Orlando,
Florida
| – | -$10.9K | -2,000 | Closed |
|
31
Northwestern Mutual Wealth Management
Milwaukee,
Wisconsin
| – | -$49 | -9 | Closed |
|
MRKR Hedge Fund Activity: Q3 2024 in Review
28 of the 6,965 institutional investors tracked by Wall St. Rank reported a position in Marker Therapeutics (MRKR) for Q3 2024, worth a combined $5.67M — down 48% from $10.9M a quarter earlier.
Fund positioning in MRKR was balanced in Q3 2024: 4 funds opened new positions, 4 closed out, 6 added to existing stakes and 3 trimmed.
The largest buyer was INVST, opening a new position worth an estimated $79.1K. The largest seller was Wedbush Securities, exiting entirely with an estimated $377K sold.
- 28 institutional investors held Marker Therapeutics (MRKR) as of Q3 2024, unchanged from Q2 2024.
- Funds reported $5.67M of Marker Therapeutics stock for Q3 2024, down 48% quarter-over-quarter.
- 4 funds opened new Marker Therapeutics positions in Q3 2024 and 4 closed out, a net change of 0 holders.
- The largest Marker Therapeutics buyer in Q3 2024 was INVST, an estimated $79.1K added.
- The largest Marker Therapeutics seller in Q3 2024 was Wedbush Securities, an estimated $377K sold.
Based on aggregated 13F filings for Q3 2024.